| Followers | 79 |
| Posts | 3015 |
| Boards Moderated | 0 |
| Alias Born | 12/04/2020 |
Monday, April 04, 2022 7:01:35 PM
No doubt it's #2, because if it was #1 the trial would have been shut down long ago. No way it gets past 700 subjects and expands into Turkey if it's not working.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
